Short Interest in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Drops By 35.9%

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 170,700 shares, a decrease of 35.9% from the January 31st total of 266,500 shares. Based on an average trading volume of 400,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.0% of the company’s stock are short sold.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ:SNSE opened at $0.43 on Tuesday. Sensei Biotherapeutics has a 12 month low of $0.38 and a 12 month high of $1.94. The firm has a market capitalization of $10.84 million, a P/E ratio of -0.36 and a beta of 0.17. The company’s fifty day moving average price is $0.49 and its 200 day moving average price is $0.51.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Sensei Biotherapeutics in a research report on Wednesday, January 8th.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. XTX Topco Ltd boosted its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,903 shares of the company’s stock after buying an additional 48,977 shares during the period. XTX Topco Ltd owned 0.25% of Sensei Biotherapeutics worth $31,000 as of its most recent SEC filing. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.